Welcome
Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Latest News
2013-05-03
First patients enrolled in phase III clinical trials of elobixibat
2013-04-26
Albireo receives 3.5 MSEK in support from VINNOVA
Go to news archive
Events
JP Morgan, San Francisco, Jan 2014
DDW, Chicago, May 2014